AUTHORS
Markus Y. Mapara, MD PhD, Elizabeth A. Shelton2, Mikhail Doubrovin3, Cecily Doonan4, Christian A Gordillo, MSc5, Hei Ton Chan, RN6, Michael Sang Hughes, MD7, Divaya Bhutani, MD8, Ran Reshef, MD, MSc9, Imo J. Akpan, MD10, Vijay Reddy, MD, PhD11, Monica Bhatia, MD12, Andrew Eisenberger, MD13
AFFILIATIONS
1 Columbia University Medical Center, New York City, New York, United States, Columbia University Medical Center, New York, New York, United States
2 Columbia University Medical Center, New York, New York, United States
3 Columbia University Medical Center, New York, New York, United States
4 Columbia University Medical Center, New York, New York, United States
5 Columbia University Medical Center, New York City, New York, United States, Columbia University Medical Center, New York, New York, United States
6 Columbia University Medical Center, New York, New York, United States
7 Columbia University Medical Center, New York City, New York, United States
8 Columbia University Medical Center, New York City, New York, United States
9 Columbia University Medical Center, New York City, New York, United States, Columbia University Medical Center, New York, New York, United States
10 Columbia University Medical Center, New York City, New York, United States
11 Actinium Pharmaceuticals, New York City, New York, United States
12 Columbia University Medical Center, Childrens Hospital of New York, New York, New York, United States
13 Columbia University Medical Center, New York City, New York, United States
ABSTRACT
Introduction: Development of novel conditioning approaches for patients with SCD is of highest interest in the context of allogeneic transplant and gene therapy platforms to overcome the short- and long-term toxicities associated with high doses of chemotherapy needed for engraftment of hematopoietic stem cells (HSC). Preceding trials (Gyurkocza et al. JCO 2025) demonstrated that Iomab-ACT (Actinium Pharmaceuticals) can safely deliver myeloablative radiation to hematopoietic and lymphoid tissues enabling successful allogeneic hematopoietic stem cell (HSC) transplantation in patients with acute myelogenous leukemia. CD45 is expressed on all white blood cells, shows dim expression of HSC and is largely absent on erythroid cells and their precursors. We hypothesized that delivery of the beta-radiation-emitting Iomab-ACT to the bone marrow and the secondary lymphoid organs would effectively deplete lymphoid cells, HSC, and erythroid precursors through either direct binding or bystander irradiation and would be therefore well suited to achieve robust donor cell engraftment with minimal regimen-related toxicity in patients with SCD and could provide a non-toxic platform without chemotherapy for future gene therapy and gene-editing approaches.
Methods: Patients with severe SCD and a fully HLA-matched sibling donor are eligible for enrollment into this Phase I trial, which studies a novel conditioning regimen consisting of 150mCi of Iomab-ACT (day -10) to deliver a radiation dose equivalent to 4 Gy to the marrow, together with standard of care 1mg/kg Alemtuzumab (day -7 to day- 2) and sirolimus (starting d-1). This conditioning regimen is intended to achieve thorough in vivo host and donor lymphodepletion to prevent Graft-versus Host Disease and graft rejection. Fully HLA-matched peripheral blood stem cells (>10x106 CD34 cells /kg) are infused on day 0. Hematopoietic recovery, lineage-specific donor chimerism, immune reconstitution, regimen-related toxicity, and laboratory markers of hemolysis are prospectively assessed.
Results: We now report the preliminary results of the first enrolled patient. A 43 y/o female patient with severe HgbSS disease including sickle cell hepatopathy, pulmonary hypertension and vaso-occlusive crises (VOC) received a stem cell graft consisting of 23.0 x 106/CD34 cells/kg/BW and 7.9 x 107 CD3 cells/kg/BW. Neutrophil and platelet engraftment occurred on days +20 and +17 respectively. Hemoglobin continuously improved and normalized by day +59 (Hgb 11.6g/dl) compared to pre-transplant (6g/dl) without any transfusion support after day +11. This was accompanied by disappearance of Hemoglobin S and gradual improvement of hemolysis markers, including haptoglobin and lactate dehydrogenase (LDH). Compared to pre-transplant, significant improvement/normalization of hemolysis markers was noted on day 180 post-transplant, i.e., indirect bilirubin 2mg/dL vs 0.3mg/dL, LDH 530U/L vs 240U/L, absolute reticulocyte count 297.5 x103/ul vs 104.4 x103/ul, haptoglobin <16mg/dL vs 36 mg/dL. In addition, the patient did not experience VOC post-transplant. Effective and prolonged host and donor lymphoid depletion was successfully achieved following treatment with Iomab-ACT and Alemtuzumab with the absolute lymphocyte count (ALC) nadiring at day 0 (0 x103/ul) and recovery of ALC > 1x103/ul starting at day +140. Multilineage donor chimerism (Myeloid, CD3+ T-cell, CD19+ B-cell, and CD56+ NK-cell compartments) was studied on days 30 (+/-7 days), 90 (+/-7 days), and 180 (+/-7 days) post-transplant using Short Tandem Repeat (STR) analysis. On days 30, 90, and 180 post-transplant donor chimerism was 99.8%, 99.7%, and 99.8% in myeloid cells; NA, 27.5%, and 36.7% in CD3+ T cells; NA, 98.6%, and 97.7% in CD19+ B cells; and 88.4%, 95%, and 96.8% in CD56+ NK cells, respectively.
Conclusions: This is the first reported use of Iomab-ACT as conditioning in SCD patients undergoing matched sibling transplant. Iomab-ACT was well tolerated and resulted in timely hematopoietic recovery, prolonged host lymphoid depletion, multilineage donor engraftment and resolution/improvement of hemolysis markers. Future enrollment will establish the minimal effective dose, safety, engraftment kinetics, and long-term benefit of Iomab-ACT as novel targeted conditioning strategy.
DISCLOSURES
Markus Y. Mapara, MD PhD: Genetix - Consultancy (Includes expert testimony); Osmium Health - Consultancy (Includes expert testimony)